SEC Tracker
Get the app

CVRx CVRX

CVRx FY 2024: revenue $51.3M, up 31%; diluted EPS −$2.65

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers CVRx reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$51.3M+31% from $39.3M in FY 202310-K income statement, on EDGAR
  2. Net income−$60.0MAgainst −$41.2M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$2.65Against −$1.99 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$105.9M+17% from $90.6M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$39.1MAgainst −$39.0M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when CVRx files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. LENSAR LNSR public float $113M, Jun 30, 2025
  2. TriSalus Life Sciences TLSI public float $112M, Jun 30, 2025
  3. KORU Medical Systems KRMD public float $119M, Jun 30, 2025
  4. InfuSystem Holdings INFU public float $122M, Jun 30, 2025
  5. Shoulder Innovations SI